FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical composition modulating activity of α7 and/or α4β2 nicotinic acetylcholine receptors, containing a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrocitrate as an active ingredient.
EFFECT: using pharmaceutical composition containing a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3,3,1,13,7]decane dihydrocitrate having high stability and poor moisture absorption.
3 cl, 9 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
AZAADAMANTANE DERIVATIVES AND METHODS FOR APPLYING | 2007 |
|
RU2450002C2 |
1-AZABICYCLO[3,3,1]NONANES DERIVATIVES | 2005 |
|
RU2445313C2 |
DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USING THEM | 2010 |
|
RU2549551C2 |
NOVEL COMPOUNDS | 2009 |
|
RU2507197C2 |
[(1H-INDOL-5-YL)-HETEROARYLOXY]-1-AZABICYCLO[3,3,1]NONANES AS CHOLINERGIC LIGANDS N-ACHR, APPLICABLE FOR PSYCHOTIC AND NEURODEGENERATIVE DISORDERS | 2006 |
|
RU2471797C2 |
AZABICYCLOALKYL ETHERS AND THEIR APPLICATION AS ALPHA7-nAChR AGONISTS | 2003 |
|
RU2352569C2 |
AZABICYCLIC ALKANE DERIVATIVES SUBSTITUTED WITH CONDENSED BICYCLOHETEROCYCLE | 2007 |
|
RU2437884C2 |
3-(HETEROARYLOXY)-2-ALKYL-1-AZABICYCLOALKYL DERIVATIVES AS LIGANDS OF ALPHA-7-nAChR (NICOTINIC ACETYLCHOLINE RECEPTORS), MEANT FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | 2005 |
|
RU2402551C2 |
P38 KINASE-INHIBITING AGENTS | 2010 |
|
RU2532376C2 |
PRODRUG OF THE AMINO ACID DERIVATIVE | 2017 |
|
RU2739318C2 |
Authors
Dates
2016-03-27—Published
2011-09-21—Filed